Jeff Edenfield, MD
Strategic Medical Advisor
Dr. Edenfield is Medical Director at the Institute for Translational Oncology Research (ITOR) at Greenville Health System (GHS) Cancer Institute, which advances care on multiple levels, including facilitating pioneering research and clinical care delivery. He oversees phase I and first-in-human clinical trials for new cancer medications and manages its Biorepository Services.
Dr. Edenfield is board certified in Medical Oncology and Hematology. He is also certified in Hospice and Palliative Medicine. He has published numerous peer-reviewed articles and has been a national principal investigator for phase l, ll, and lll oncology trials. He is a member of the American Society of Clinical Oncology and is the Academic Vice Chair for Oncology in the Greenville Health System, where he is currently an Associate Professor in the Department of Medicine. His extensive experience in the application of genomic information on patient care has driven a focus on enabling patients with access to quality clinical trials.
Dr. Edenfield earned his Medical Degree from the University of Miami, Florida. He completed his internship, residency, and fellowship at Walter Reed Army Medical Center in Washington, D.C. Dr. Edenfield also completed a research fellowship in Hematologic Malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his active duty service obligation, obtaining the rank of Major, as Chief of Oncology at Womack Army Medical Center in North Carolina.
“I am hopeful about the many new treatments emerging for my patients. Every day there are new pathways of drug approval, which are accelerating the options for keeping them well. However, we are reaching only a small fraction of patients with respect to clinical trial enrollment. With hundreds of new drugs needing to be studied, innovative methods to inform physicians and match patients to these trials have never been more important. Doubling the number of adults who join oncology clinical trials from three percent to six percent would be a tremendous accomplishment, and Inteliquet is uniquely positioned to move us in that direction.”
HOW NEW THERAPIES REACH PATIENTS FASTER